Impact of cancer history on clinical outcome in patients undergoing transcatheter edge-to-edge mitral repair
Open Access
- 9 November 2020
- journal article
- research article
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 110 (3) , 440-450
Abstract
Background: Little is known about the prevalence of a history of cancer and its impact on clinical outcome in mitral regurgitation (MR) patients undergoing transcatheter mitral valve repair (TMVR).Objectives: The purpose of this study is to investigate the prevalence of cancer, baseline inflammatory parameters, and clinical outcome in MR patients undergoing TMVR.Methods: Consecutive patients undergoing a MitraClip procedure were enrolled, and the patients were stratified into two groups: cancer and non-cancer. Baseline complete blood counts (CBC) with differential hemograms were collected prior to the procedure to calculate the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR). All-cause death within a one-year was examined.Results: In total, 82 out of 446 patients (18.4%) had a history of cancer. Cancer patients had a significantly higher baseline PLR [181.4 (121.1–263.9) vs. 155.4 (109.4–210.4);P = 0.012] and NLR [5.4 (3.5–8.3) vs. 4.0 (2.9–6.1);P = 0.002] than non-cancer patients. A Kaplan–Meier analysis revealed that cancer patients had a significantly worse prognosis than non-cancer (estimated 1-year mortality, 20.2 vs. 9.2%; log-rankP = 0.009), and multivariable analyses of three models showed that cancer history was an independent factor for 1-year mortality. Patients who died during follow-up had a significantly higher baseline PLR [214.2 (124.2–296.7) vs. 156.3 (110.2–212.1);P = 0.007] and NLR [6.4 (4.2–12.5) vs. 4.0 (2.9–6.2);P < 0.001] than survivors.Conclusions: In MitraClip patients, a history of cancer was associated with higher inflammatory parameters and worse prognosis compared to non-cancer patients.Graphical Central Illustration. Clinical outcomes and baseline PLR and NLR values accord-ing to one-year mortality. (Left) Patients who died within the follow-up period had a significantly higher baseline PLR (214.2 [124.2–296.7] vs 156.3 [110.2–212.1];P= 0.007) and NLR (6.4 [4.2–12.5] vs 4.0 [2.9–6.2];P< 0.001) than patients who survived. PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio (Right) A Kaplan-Meier analysis revealed that cancer patients had a significantly worse prognosis than non-cancer patients (estimated one-year mortality, 20.2 vs 9.2%; log-rankP= 0.009).Keywords
Funding Information
- Universitätsklinikum Bonn
This publication has 34 references indexed in Scilit:
- Cancer treatment and survivorship statistics, 2016CA: A Cancer Journal for Clinicians, 2016
- Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysisAnnals of Surgical Oncology, 2015
- Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio are Predictors of Heart FailureArquivos Brasileiros de Cardiologia, 2015
- Percutaneous Mitral Valve Edge-to-Edge RepairJACC, 2014
- Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic StrategiesMedicinal Chemistry, 2014
- An emerging double burden of disease: the prevalence of individuals with cardiovascular disease and cancerJournal of Internal Medicine, 2013
- Percutaneous Mitral Valve Interventions in the Real WorldJACC, 2013
- The Potential Role of Neutrophils in Promoting the Metastatic Phenotype of Tumors Releasing Interleukin-8Clinical Cancer Research, 2004
- Inflammation and cancerNature, 2002
- Inflammation and cancer: back to Virchow?The Lancet, 2001